[1] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15(1):11-20.
[2] Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class i-related gene a promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res, 2017, 8(4):343-349.
[3] Mohamed AA, Ahmed HH, ElSadek SM, et al. Astudy of leptin and its gene 2548 g/a rs7799039 single-nucleotide polymorphisms in Egyptian children: a single-center experience. Clin Res Hepatol Gastroenterol, 2021, 45(5):101724.
[4] Arab JP, Barrera F, Arrese M. The evolving role of liver biopsy in non-alcoholic fatty liver disease. Ann Hepatol, 2018, 17(6):899-902.
[5] Yilmaz Y, Toraman AE, Alp C, et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther, 2022, 10(1111/apt):17301.
[6] Barchetta I, Cimini FA, Leonetti F, et al. Increased plasma proneurotensin levels identify nafld in adults with and without type 2 diabetes. J Clin Endocr Metab, 2018, 103(6):2253-2260.
[7] Abd-Elsalam S, Hanafy AS. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. J Hepatol, 2018, 68:S210-S210.
[8] Barranco-Fragoso B, Pal SC, Díaz-Orozco LE, et al. Identification of hepatic dendritic cells in liver biopsies showing steatosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) associated with obesity. Med Sci Monit, 2022, 28:e937528.
[9] Koínková L, Pražienková V, Černá L, et al. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Front Endocrinol (Lausanne), 2020, 11:597583.
[10] Soliman H, Ziada D, Salama M, et al. Predictors for fibrosis regression in chronic HCV patients after the treatment with DAAs: results of a real-world cohort study. Endocr Metab Immune, 2020, 20(1):104-111.
[11] Ghoneem E, Mohamed SM, Elemshaty W, et al. Insulin like growth factor-1 as a prognostic tool for overall survival in chronic hepatitis C cirrhotic Egyptian patients with hepatocellular carcinoma. J Hepatol, 2021, 75:S494-S495.
[12] Watany M, Badawi R, Elkhalawany W, et al. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res, 2017, 11(2):Oc32-Oc34.
[13] De Marco G, Romaniello M, Roviello A. Psychological NASH equilibria under ambiguity. Math Soc Sci, 2022, 120:92-106.
[14] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[15] Luong XG, Stevens SK, Jekle A, et al. Regulation of gene transcription by thyroid hormone receptor beta agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS One, 2020, 15(12):e0240338.
[16] Gallage S, Ali A, Barragan Avila JE, et al. Spontaneous cholemia in c57bl/6 mice predisposes to liver cancer in nash. Cell Mol Gastroenterol Hepatol, 2022, 13(3):875-878.
[17] Bravo M, Raurell I, Hide D, et al. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. Sci Rep, 2019, 9(1):20183.
[18] Dongiovanni P, Meroni M, Longo M, et al. Genetics, immunity and nutrition boost the switching from NASH to HCC. Biomedicines, 2021, 9(11):1524.
[19] Al-Ajmi M. Observational limits on the NASH theory of gravity with matter contents. Int J Geom Methods M, 2022, 13(3):875-878.
[20] Hartimath SV, Boominathan R, Soh V, et al. Imaging fibrogenesis in a diet-induced model of nonalcoholic steatohepatitis (NASH). Contrast Media Mol Imaging, 2019, 2019:6298128.
[21] Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs, 2020, 29(2):151-161. |